Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124556 | 1.00 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL15143001 | 1.00 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL3192032 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL98457 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL5575317 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL6206953 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL6479731 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL223631 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL7158782 | 0.83 | POLB (0.58) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL20123343 | 0.83 | POLB (0.58) | POLBGAAALOX12HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | POLB 1787/4885GAA 1244/4885ALOX12 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.